A group from the University of California, Santa Cruz, has embarked on a new project to commercialize cancer genomics software through a new startup company called Five3 Genomics. The company has attracted a few of the biggest names in genomics and biotech to serve as advisers.
The Pittsburgh-based health group has tapped Oracle, IBM, Informatica and dbMotion for technology in the $100 million project, which will give clinicians, researchers, administrators and others real-time access to data and analytics, UPMC announced Oct. 1.
Life Technologies ($LIFE) just sealed a multi-year deal with CollabRx ($CLRX) intended to supercharge the value of its molecular diagnostics tests with lots of data.
There's a new trend in research: using mice as avatars, or stand-ins, of sorts--personal guinea pigs for patients seeking the best possible cancer treatment.
A finding that there are four main genetic subtypes of breast cancer creates enormous new opportunities for diagnostics companies. And the research, conducted by the Cancer Genome Atlas project and published in the journal Nature, could further upend the diagnostics industry as the science behind personalized medicine continues to advance, Bloomberg reports.
Foundation Medicine has pulled in a sizeable $42.5 million Series B financing round, seriously juicing its capacity to support commercial sales of its signature molecular diagnostic test and advance another one in the pipeline.
BioFire Diagnostics has pulled in $25 million in new funding to accelerate product development of signature tests.
California's Life Technologies ($LIFE) is the latest Dx player to catch the eye of Big Pharma. The Carlsbad company will partner with Bristol-Myers Squibb ($BMY) to develop a number of new companion diagnostics.
GE Healthcare ($GE) will invest nearly $33 million as part of a multifaceted deal with the University of Wisconsin to boost collaboration on new imaging and diagnostics technology, and generate a robust stream of technology and patents.
Merck Serono has launched a second spinoff company, Quartz Bio, which will focus on biomarker data management and analysis for pharma companies developing new drugs. The biomarker information will allow companies to select the patients most likely to respond in clinical trials, as well as help doctors to tailor treatment to individual patients once drugs reach the market.